Could a common antibiotic stop a blood cancer before it starts?
NCT ID NCT07209371
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the antibiotic rifaximin can reduce abnormal proteins in people with a precancerous blood condition called IgA MGUS. About 50 adults will either receive the drug or no treatment. The goal is to see if rifaximin can lower the risk of progression to multiple myeloma.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States